One-year clinical outcomes of patients implanted with a Resolute Onyx™ zotarolimus-eluting stent

Autor: Kelvin Y.K. Chan, Arthur Yung, Simon S. K. Lam, Yui Ming Lam, CW Chan, Chor Cheung Tam, David C.W. Siu, Hung-Fat Tse
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Target lesion
Male
medicine.medical_specialty
Medicine (General)
Time Factors
medicine.medical_treatment
Population
Myocardial Infarction
Coronary Artery Disease
030204 cardiovascular system & hematology
Coronary Angiography
Biochemistry
03 medical and health sciences
0302 clinical medicine
Percutaneous Coronary Intervention
R5-920
Coronary thrombosis
medicine
Diabetes Mellitus
Humans
030212 general & internal medicine
Myocardial infarction
Registries
education
Aged
Retrospective Studies
Sirolimus
education.field_of_study
Clinical Report
business.industry
Coronary Thrombosis
Biochemistry (medical)
Percutaneous coronary intervention
Stent
Retrospective cohort study
Drug-Eluting Stents
Cell Biology
General Medicine
Middle Aged
medicine.disease
Survival Analysis
Surgery
zotarolimus-eluting stent
Treatment Outcome
Drug-eluting stent
Female
business
Immunosuppressive Agents
Zdroj: Journal of International Medical Research, Vol 46 (2018)
The Journal of International Medical Research
ISSN: 1473-2300
0300-0605
Popis: Objective To evaluate the 1-year clinical outcomes of patients who received the Resolute Onyx™ stent. Methods This was a single-centre, retrospective registry analysis that reviewed the clinical data from all patients who were implanted with a Resolute Onyx™ stent between March 2015 and February 2016. Clinical follow-up was performed at 1 year post-implantation. Results A total of 252 patients received a Resolute Onyx™ stent and two patients were lost to follow-up. The mean age of the cohort was 66.9 years and 113 (45.2%) had diabetes mellitus. Thirty-eight patients (15.2%) had left main disease and 73 (29.2%) had three-vessel disease. A total of 175 patients (70.0%) had small vessel disease (20 mm). The 1-year target lesion failure was 4.4% (11 of 250), cardiovascular death occurred in eight patients (3.2%), ischaemia-driven target lesion revascularization was undertaken in five patients (2.0%) and stent thrombosis occurred in one patient (0.4%). Conclusion The Resolute Onyx™ stent showed a favourable 1-year clinical performance in a real-world population.
Databáze: OpenAIRE
Externí odkaz: